PAR-22-090: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) (PAR-25-346). Status: Due dates in the notice, expires January 7, 2028. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 10, 2024.
From the official notice on Grants.gov, last changed December 11, 2024. Checked November 7, 2026.
- Award ceiling$275,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNCI, NIDCR, NIAMS
- Median yearly award$217,875
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-22-090 were run by National Cancer Institute (NCI, 28 projects), National Institute of Dental and Craniofacial Research (NIDCR, 3 projects) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-090 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-346 | December 11, 2024 | Due dates in the notice, expires January 7, 2028 | Open |
Key dates
| Posted | January 11, 2022 |
|---|---|
| Deadline | December 10, 2024 |
| Archived by Grants.gov | January 9, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $217,875; it allows up to $275,000 per award.
- Most of the money in the 7 programs behind this notice (64% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
Funded under PAR-22-090 so far
NIH funded 33 projects under PAR-22-090 in fiscal 2023 to 2026, at 29 institutions. The median yearly award was $217,875.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Advanced 3D auxetic biodegradable implant for large volume breast reconstruction | Georgia Institute of Technology | 2026 | $253,965 |
| Halting Breast Cancer Metastasis by Blocking Cancer-MSC Engulfment | University of Pittsburgh at Pittsburgh | 2026 | $217,659 |
| Heating Magnetic Nanoparticles using Low Frequency Ferromagnetic Resonance | Dartmouth-Hitchcock Clinic | 2026 | $182,683 |
| Synthetic Mechano-Transduction For Improved Cell Therapies In Immuno-Oncology | Yale University | 2026 | $235,212 |
| Tumor-site activated T cell redirecting autoantibodies | University of Pennsylvania | 2026 | $182,764 |
| A Pathomimetic Gingiva-on-a-Chip for Assessing Microbiota-Directed Anti-Inflammatory Therapeutics | Cleveland Clinic Lerner Com-Cwru | 2025 | $442,750 |
| Improving Accuracy of Next-Generation Microscopy for Early Stage Metastatic Melanoma Detection | Duke University | 2025 | $188,169 |
| Enhanced treatment of breast cancer via biodegradable polymer nanoparticles | University of Pennsylvania | 2025 | $391,826 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Other programs behind this notice
- Cancer Detection and Diagnosis Research
- Arthritis, Musculoskeletal and Skin Diseases Research
- Oral Diseases and Disorders Research
- Cancer Control
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-346, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-090 still open?
No. It closed on December 10, 2024. A newer notice is open: PAR-25-346, due dates in the notice, expires January 7, 2028.
Who can apply for Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)?
Closed December 10, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $275,000 each.
Who has been funded under PAR-22-090?
NIH RePORTER lists 33 projects funded under PAR-22-090 in fiscal 2023 to 2026, at 29 institutions. The most were at University of Pennsylvania, Duke University, Virginia Polytechnic Inst and St Univ.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)